Company / Cash & Equivalents
Revolution Medicines, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$383.7M
FY2025
5-year range
$104.3M / $696.1M
FY2021-FY2025
Trend
-29.3%
vs FY2024
Sector context
#50 of 207
Health Care
What the data says
Revolution Medicines, Inc.'s cash & equivalents of $384M is higher than 76% of companies in the Health Care sector (FY2025). Declined from $696M to $384M over the past 2 years.
Based on SEC 10-K filings.
$384M in FY2025 with a 5-year CAGR of +87.3%. Top quartile in the Health Care sector.
Declined from $696M to $384M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +52.4%
- 5-Year CAGR
- +87.3%
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 207This company $383.7M Sector average $669.5M
▼
-42.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +87.3%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 29.3% year-over-year.
- Ranks #50 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $383.7M | -29.3% |
| FY2024 | $543.1M | -22.0% |
| FY2023 | $696.1M | +541.6% |
| FY2022 | $108.5M | +4.1% |
| FY2021 | $104.3M | +525.9% |
| FY2020 | $16.7M | +0.0% |
| FY2019 | $16.7M | -76.1% |
| FY2018 | $69.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026